--- title: "Weekly Recap | LLY 2X Long ETF +13.44%, closing in on record highs" type: "News" locale: "en" url: "https://longbridge.com/en/news/302161662.md" description: "The LLY 2X Long ETF rose 13.44% this week to close at $28.53. The S&P 500 fell 1.95% over the same period, leaving the fund roughly 15.39 percentage points ahead. The week started weak: the fund dipped to $24.29 on Tuesday before running higher from Wednesday. Thursday delivered a 6.65% single-day gain, and Friday set a fresh weekly high of $29.25 before settling at $28.53." datetime: "2026-10-17T04:41:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/302161662.md) - [en](https://longbridge.com/en/news/302161662.md) - [zh-HK](https://longbridge.com/zh-HK/news/302161662.md) generator: "portal-rs" --- # Weekly Recap | LLY 2X Long ETF +13.44%, closing in on record highs ## The Week The LLY 2X Long ETF rose 13.44% this week to close at $28.53. The S&P 500 fell 1.95% over the same period, leaving the fund roughly 15.39 percentage points ahead. The week started weak: the fund dipped to $24.29 on Tuesday before running higher from Wednesday. Thursday delivered a 6.65% single-day gain, and Friday set a fresh weekly high of $29.25 before settling at $28.53. ## Eli Lilly This Week Eli Lilly gained 6.59% to close at $1,257.03. The stock followed a similar pullback-then-rally pattern, with Wednesday marking the start of a volume-backed push. Thursday saw the stock touch a weekly high of $1,275.88. Trading activity picked up sharply, with Thursday’s volume of roughly 37.6m shares running well above the weekly average. ## Leverage & Decay This product replicates twice the daily move in Eli Lilly, not twice the weekly move. The theoretical weekly gain was about 13.18%, against an actual gain of 13.44%, giving a positive gap of 0.26 percentage points. That gap comes from daily rebalancing. In a trending week the decay drag is limited; in a choppy, sideways market it tends to widen. Holding the fund long is not the same as earning 2x the underlying’s return over time. ## Eli Lilly News The week’s news centred on two items: Omvoh data showing comprehensive disease control in ulcerative colitis patients, and European regulatory backing for the GLP-1 weight-loss pill. At the same time, money rotated out of AI tech and into healthcare, lifting Eli Lilly more than 5% intraday on Thursday. The stock closed near its $1,292 record high, with market value back above $1.2tn. ## Eli Lilly — Analyst Ratings Among the 33 institutions covering Eli Lilly, 20 rate it buy, 6 overweight, 3 hold, 1 underweight, 1 sell, and 2 have no opinion. The consensus rating is buy, with a consensus target of $1,328.05, about 5.65% above the last close of $1,257.03. Target prices range from $930 to $1,600, pointing to a wide spread. Coverage rank is first within the pharmaceutical industry. ## The Week Ahead The macro calendar next week includes US NAHB housing data, housing starts and building permits, and EIA crude inventories. The main event for the underlying is Eli Lilly’s Q3 FY2026 earnings on 29 October, with estimates at EPS of $8.08 and revenue of $22.5bn. Until then, the key question is whether the defensive rotation into healthcare holds, and whether the Omvoh and weight-loss drug stories produce follow-through news. ## In Short The tension this week sits between a constructive ratings picture and a leverage-linked risk profile. Most brokers rate Eli Lilly buy or overweight, and the consensus target sits about 5.65% above spot, while the rotation out of tech pushed healthcare into a safe-haven role and helped the fund outperform. But the target price range is wide, and the 2x structure can amplify drawdowns in a choppy market. What comes next depends on the earnings print and whether the defensive bid persists. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md) ## Related News & Research - [Eli Lilly and Company $LLY Stock Acquired by China Universal Asset Management Co. Ltd.](https://longbridge.com/en/news/303851739.md) - [BUZZ-Street View: Next-generation drugs bolster Lilly's growth outlook](https://longbridge.com/en/news/303725218.md) - [Hubbell: 3 key takeaways for long-term investors](https://longbridge.com/en/news/304775832.md) - [Is Corning (GLW) Undervalued After Strong Earnings And Higher Guidance?](https://longbridge.com/en/news/304790245.md) - [Trade Desk Stock Is 90% Below Its High. Can Earnings Turn the Tide?](https://longbridge.com/en/news/304769650.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**